2025
Impact of multi-level factors and partner characteristics on antiretroviral therapy adherence and access to HIV care during the COVID-19 pandemic
Neuenschwander P, Pala A, Altice F, Remien R, Mergenova G, Rozental E, Gulyayev V, Davis A. Impact of multi-level factors and partner characteristics on antiretroviral therapy adherence and access to HIV care during the COVID-19 pandemic. International Journal Of STD & AIDS 2025, 36: 568-576. PMID: 40155324, DOI: 10.1177/09564624251329626.Peer-Reviewed Original ResearchConceptsAntiretroviral therapy adherenceMental healthFactors associated with ART adherenceMethodsA cross-sectional surveyMultilevel generalized linear mixed modelsPoor mental healthAssociated with lower adherenceBackgroundAdherence to antiretroviral therapyAntiretroviral therapyMedication adherence ratesCross-sectional surveyCOVID-19 pandemicHIV treatment programsMulti-level factorsNegative emotional impactHIV carePublic health crisisSocial supportART adherenceSupportive partnersLinear mixed modelsAdherence ratesAssessed associationsLow adherenceAdherence levels
2022
Viral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone
Gonzales P, Bachireddy C, Grieco A, Ding R, de Leon S, Ulrich A, Lama J, Duerr AC, Altice FL. Viral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 89: 462-471. PMID: 34897226, PMCID: PMC8881312, DOI: 10.1097/qai.0000000000002889.Peer-Reviewed Original ResearchConceptsMSM/transgender womenAlcohol use disorderOral naltrexoneTransgender womenViral suppressionUse disordersEFV/TDF/FTCTreatment of AUDMaximal viral suppressionSingle treatment regimenPlacebo-controlled trialTDF/FTCAntiretroviral therapy adherenceUse of naltrexoneEvidence-based treatmentsViral suppression levelsMVs levelsSecondary outcomesTherapy adherenceLow adherenceAdherence levelsNaltrexoneAUD treatmentHIVPlacebo
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply